These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


325 related items for PubMed ID: 16278881

  • 21. Treatment of osteogenesis imperfecta: who, why, what?
    Glorieux FH.
    Horm Res; 2007; 68 Suppl 5():8-11. PubMed ID: 18174695
    [Abstract] [Full Text] [Related]

  • 22. Effects of bisphosphonates on tooth eruption in children with osteogenesis imperfecta.
    Kamoun-Goldrat A, Ginisty D, Le Merrer M.
    Eur J Oral Sci; 2008 Jun; 116(3):195-8. PubMed ID: 18471236
    [Abstract] [Full Text] [Related]

  • 23. Osteogenesis imperfecta.
    Huber MA.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):314-20. PubMed ID: 17223585
    [Abstract] [Full Text] [Related]

  • 24. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D, Coker M, Darcan S, Köse T, Kara S.
    Turk J Pediatr; 2006 Mar; 48(2):124-9. PubMed ID: 16848111
    [Abstract] [Full Text] [Related]

  • 25. Large osteoclasts in pediatric osteogenesis imperfecta patients receiving intravenous pamidronate.
    Cheung MS, Glorieux FH, Rauch F.
    J Bone Miner Res; 2009 Apr; 24(4):669-74. PubMed ID: 19063679
    [Abstract] [Full Text] [Related]

  • 26. Reduction of plasma taurine level in children affected by osteogenesis imperfecta during bisphosphonate therapy.
    D'Eufemia P, Finocchiaro R, Zambrano A, Tetti M, Ferrucci V, Celli M.
    Biomed Pharmacother; 2007 May; 61(4):235-40. PubMed ID: 17275249
    [Abstract] [Full Text] [Related]

  • 27. Alendronate treatment in osteogenesis imperfecta.
    Madenci E, Yilmaz K, Yilmaz M, Coskun Y.
    J Clin Rheumatol; 2006 Apr; 12(2):53-6. PubMed ID: 16601536
    [Abstract] [Full Text] [Related]

  • 28. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
    Alharbi M, Pinto G, Finidori G, Souberbielle JC, Guillou F, Gaubicher S, Le Merrer M, Polak M.
    Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235
    [Abstract] [Full Text] [Related]

  • 29. Effect of intravenous pamidronate therapy on functional abilities and level of ambulation in children with osteogenesis imperfecta.
    Land C, Rauch F, Montpetit K, Ruck-Gibis J, Glorieux FH.
    J Pediatr; 2006 Apr; 148(4):456-60. PubMed ID: 16647404
    [Abstract] [Full Text] [Related]

  • 30. Osteogenesis Imperfecta: update on presentation and management.
    Cheung MS, Glorieux FH.
    Rev Endocr Metab Disord; 2008 Jun; 9(2):153-60. PubMed ID: 18404382
    [Abstract] [Full Text] [Related]

  • 31. Oral alendronate in osteogenesis imperfecta.
    Unal E, Abaci A, Bober E, Buyukgebiz A.
    Indian Pediatr; 2005 Nov; 42(11):1158-60. PubMed ID: 16340059
    [Abstract] [Full Text] [Related]

  • 32. Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome.
    Bajpai A, Kabra M, Gupta N, Sharda S, Ghosh M.
    J Pediatr Orthop; 2007 Mar; 27(2):225-7. PubMed ID: 17314651
    [Abstract] [Full Text] [Related]

  • 33. Update on the evaluation and treatment of osteogenesis imperfecta.
    Harrington J, Sochett E, Howard A.
    Pediatr Clin North Am; 2014 Dec; 61(6):1243-57. PubMed ID: 25439022
    [Abstract] [Full Text] [Related]

  • 34. Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.
    Weber M, Roschger P, Fratzl-Zelman N, Schöberl T, Rauch F, Glorieux FH, Fratzl P, Klaushofer K.
    Bone; 2006 Sep; 39(3):616-22. PubMed ID: 16644299
    [Abstract] [Full Text] [Related]

  • 35. Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report.
    Olson JA.
    J Pediatr Rehabil Med; 2014 Sep; 7(2):155-8. PubMed ID: 25096867
    [Abstract] [Full Text] [Related]

  • 36. Transient disturbance in physeal morphology is associated with long-term effects of nitrogen-containing bisphosphonates in growing rabbits.
    Smith EJ, Little DG, Briody JN, McEvoy A, Smith NC, Eisman JA, Gardiner EM.
    J Bone Miner Res; 2005 Oct; 20(10):1731-41. PubMed ID: 16160731
    [Abstract] [Full Text] [Related]

  • 37. Bisphosphonate treatment of pediatric bone disease.
    Speiser PW, Clarson CL, Eugster EA, Kemp SF, Radovick S, Rogol AD, Wilson TA, LWPES Pharmacy and Therapeutic Committee.
    Pediatr Endocrinol Rev; 2005 Dec; 3(2):87-96. PubMed ID: 16361982
    [Abstract] [Full Text] [Related]

  • 38. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series.
    Schwartz S, Joseph C, Iera D, Vu DD.
    J Can Dent Assoc; 2008 Dec; 74(6):537-42. PubMed ID: 18644240
    [Abstract] [Full Text] [Related]

  • 39. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F, Munns C, Land C, Glorieux FH.
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [Abstract] [Full Text] [Related]

  • 40. Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
    Biggin A, Munns CF.
    Curr Osteoporos Rep; 2017 Oct; 15(5):412-418. PubMed ID: 28823022
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 17.